Clinical implications for the use of a biomarker for subclinical rejection - Conflating arguments cause a disconnection between the premise and the conclusion
- PMID: 30809931
- DOI: 10.1111/ajt.15327
Clinical implications for the use of a biomarker for subclinical rejection - Conflating arguments cause a disconnection between the premise and the conclusion
Keywords: biomarker; kidney transplantation/nephrology; rejection: subclinical; translational research/science.
Comment on
-
Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant.Am J Transplant. 2019 Jan;19(1):98-109. doi: 10.1111/ajt.15011. Epub 2018 Aug 31. Am J Transplant. 2019. PMID: 29985559 Free PMC article.
-
The special relativity of noninvasive biomarkers for acute rejection.Am J Transplant. 2019 Jan;19(1):5-8. doi: 10.1111/ajt.15078. Epub 2018 Sep 17. Am J Transplant. 2019. PMID: 30125470 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
